Nifty Pharma index extends fall; Lupin hits 52-week low
Sun Pharma, Dr Reddy's Lab, Glenmark Pharma and Lupin were down 3% on NSE
)
premium
Govt proposes to bring fixed-dose combinations under price control
Shares of pharmaceutical companies continued to trade under pressure with Nifty Pharma index down more than 1% for the third straight trading sessions after firms reported a disappointing set of numbers for the quarter ended June 2017 (Q1FY18).
At 2:57 pm; Nifty Pharma index, the largest loser among sectoral indices, was down 2% as compared to 0.43% rise in the Nifty 50 index. In past three trading sessions, the pharma index slipped 5.6% against 0.36% rise in the benchmark index.
Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals and Lupin were down up to 3% on the National Stock Exchange (NSE).
At 2:57 pm; Nifty Pharma index, the largest loser among sectoral indices, was down 2% as compared to 0.43% rise in the Nifty 50 index. In past three trading sessions, the pharma index slipped 5.6% against 0.36% rise in the benchmark index.
Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals and Lupin were down up to 3% on the National Stock Exchange (NSE).